Abstract
Capsule summary:•These 2 case series described the use of oral tofacitinib to treat severe alopecia areata (AA) in children aged 4-10 years.•Doses ranged from 2.5 mg daily in patients aged 4-5 years to 5 mg twice daily in patients aged 8-10 years.1,2•Of the 7 patients described, 6 achieved at least 50% improvement after 3- 21 months of treatment.1,2 Side effects included diarrhea (2 patients) and upper respiratory infection (1 patient), which resolved despite continuous therapy.2How did this article change the practice of dermatology?•Oral tofacitinib may be considered a treatment option for preadolescent children with severe AA resulting in psychosocial impairment, with appropriate counseling on potential adverse effects, such as infections and malignancies.•These results are promising as extensive AA in children may have a profound negative impact on the quality of life and treatments have been limited thus far.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
